Properties (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medication
|
| gptkbp:activeDuring |
Carbamazepine
|
| gptkbp:brand |
gptkb:Carbatrol
gptkb:Equetro Tegretol |
| gptkbp:clinicalTrials |
Phase IV
|
| gptkbp:contraindication |
gptkb:Stevens-Johnson_syndrome
Hyponatremia Aplastic anemia Bone marrow suppression Hypersensitivity to carbamazepine Liver dysfunction Toxic epidermal necrolysis |
| gptkbp:date |
1998-01-01
|
| gptkbp:dosageForm |
Capsule
|
| gptkbp:formulation |
Extended-release capsule
|
| gptkbp:gestationPeriod |
D
|
| gptkbp:healthcare |
Avoid alcohol
Take with food Do not stop abruptly Regular follow-up appointments required Report rash immediately |
| https://www.w3.org/2000/01/rdf-schema#label |
Carbatrol
|
| gptkbp:interactsWith |
Warfarin
Antidepressants Oral contraceptives Monoamine oxidase inhibitors |
| gptkbp:is_monitored_by |
Electrolytes
Liver function tests Complete blood count |
| gptkbp:mandates |
Bipolar disorder
Trigeminal neuralgia |
| gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
| gptkbp:numberOfStudents |
25 to 65 hours
|
| gptkbp:nutritionalValue |
Liver
|
| gptkbp:route |
Oral
|
| gptkbp:sideEffect |
Dizziness
Nausea Vomiting Blurred vision Drowsiness |
| gptkbp:skills |
100 mg
200 mg 300 mg |
| gptkbp:usedFor |
gptkb:Epilepsy
|
| gptkbp:waterManagement |
Urine
Feces |